The Autopsy / Case File · Chronic Disease Progression
Never Screened
Most cancer deaths in America are the end of a treatment story — a disease that was found and fought and won anyway. Two cancers are different. Cervical and colorectal cancer are both slow, both preceded by a detectable precursor lesion, and both survivable at a rate above ninety percent when they are caught while still confined to where they started. When people die of them, the decisive event usually happened years earlier, in an exam room nobody ever walked into.
The National Cancer Institute's SEER program puts five-year relative survival for localized colorectal cancer at 91.3 percent and for distant colorectal cancer at 16.9 percent. For cervical cancer the same split is 91.8 percent localized against 20.5 percent distant. Twenty-three percent of colorectal cancers and sixteen percent of cervical cancers are already distant at diagnosis. Meanwhile, according to the 2023 National Health Interview Survey, only 37.1 percent of adults aged 45 to 49 were up to date on colorectal screening, and a study published in JAMA Network Open in August 2026 found that the share of American women aged 21 to 29 who have never been screened for cervical cancer rose from 12.5 percent in 2005 to 31.9 percent in 2023.
Join the discussion →
Screening is not treatment, and the distinction is not semantic. A treatment improves the odds of surviving a cancer you already have. A screening test changes which cancer you have — it moves the diagnosis backward in time, to a stage where the disease is smaller, more contained, and vastly more curable, and in the case of colorectal and cervical cancer it can catch the disease before it is a disease at all. A colonoscopy that finds and removes an adenomatous polyp has not detected cancer early; it has deleted a cancer from the future. A Pap test or an HPV test that catches high-grade cervical dysplasia does the same thing. That is why the mortality arithmetic for these two cancers runs through the screening schedule rather than the oncology ward, and why a person who dies of either one is usually not a story about a treatment that failed.
The Stage Is the Prognosis
The survival numbers make the mechanism unusually legible. SEER's most recent five-year relative survival estimates, covering cases diagnosed from 2016 through 2022, put colorectal cancer at 91.3 percent when localized, 75.2 percent when it has reached regional lymph nodes, and 16.9 percent once it has metastasized to distant sites. Cervical cancer runs 91.8 percent localized, 64.0 percent regional, and 20.5 percent distant. In both cancers, the drop from localized to distant is not incremental — it is a collapse of roughly seventy-five percentage points, the difference between a disease most people walk away from and a disease most people do not.
Now look at where American patients actually enter that distribution. Only 34 percent of colorectal cancers are diagnosed while still localized; 37 percent are regional, 23 percent are distant, and 6 percent go unstaged. Cervical cancer is somewhat better at the front end and still not good: 41 percent localized, 37 percent regional, 16 percent distant, 6 percent unknown. SEER's 2026 projections put colorectal cancer at 158,850 new cases and 55,230 deaths, and cervical cancer at 13,490 new cases and 4,200 deaths. Those death counts are not primarily a measure of how well American oncology treats advanced disease. They are a measure of how many patients arrived already advanced.
The Screen That Never Happened
For cervical cancer, the under-screened population has been the identified driver for decades. CDC's Vital Signs analysis of cervical cancer incidence, mortality, and screening — covering 2007 through 2012 — found that roughly one in ten women aged 21 to 65, 11.4 percent, had not been screened in the previous five years, and stated flatly that over half of all new cervical cancer cases occur in women who have never or rarely been screened. The unscreened share was roughly double among women without insurance, at 23.1 percent, and among women with no regular health care provider, at 25.5 percent. The South had both the highest cervical cancer death rate in the country, 2.7 per 100,000, and the highest share of unscreened women.
What has changed since is the direction. A study published in JAMA Network Open on August 27, 2026, by Sonawane, Damgacioglu, Amboree and colleagues, drawing on nine cycles of the National Health Interview Survey from 2005 through 2023, found that the proportion of women aged 21 to 29 who had never been screened for cervical cancer rose from 12.5 percent in 2005 — about 3.5 million women — to 31.9 percent in 2023, about 6.2 million, an average annual increase of 5.2 percent. Among women aged 30 to 65, never-screening rose from 5.3 percent to 14.8 percent, from 4.3 million women to 9.2 million, at an average annual rate of 6.8 percent. HPV vaccination climbed steeply over the same period, from 5.7 percent of women aged 21 to 29 in 2008 to 54.0 percent in 2019, which reduces but does not eliminate cervical cancer risk — and roughly a third of the women in that age group who remain unvaccinated have also never been screened, meaning the two protections are failing in the same people rather than covering for each other.
The Age the Guideline Moved To
Colorectal cancer has its own specific and recent gap. In 2021 the U.S. Preventive Services Task Force lowered the recommended age to begin average-risk colorectal cancer screening from 50 to 45, a response to rising incidence in younger adults. The guideline moved. Behavior did not follow it quickly. CDC's analysis of 2023 National Health Interview Survey data found that just 37.1 percent of adults aged 45 to 49 were up to date on colorectal screening, with a 95 percent confidence interval of 34.5 to 39.7 percent. In the next age bracket up, 50 to 64, the figure was 67.8 percent, and among adults 65 to 75 it was 82.7 percent. The newest cohort of eligible adults is screened at less than half the rate of the oldest, and the five-year window in which their guideline has existed is exactly the window in which a missed adenoma becomes a tumor.
Insurance is the other axis, and it is stark. Among adults under 65 in the same 2023 survey, colorectal screening was up to date for 64.7 percent of those with private insurance and 23.8 percent of the uninsured — a gap of roughly forty percentage points on a test whose entire value is that it happens on schedule. Screening prevalence overall has been improving slowly; CDC's chronic disease center reports 61 percent of adults aged 45 to 75 up to date in 2022 using BRFSS data. But the improvement is concentrated in the populations that were already being screened, and the deficits are concentrated in the populations already dying at higher rates.
Screening does not improve your odds of surviving the cancer you have. It changes which cancer you have — and for these two, that is nearly the whole difference between living and not.
What the Gap Costs, Counted
CDC has actually modeled the body count. A 2020 analysis published in the agency's journal Preventing Chronic Disease, by Sharma and colleagues, took single-year birth cohorts — 21-year-old women for cervical cancer, 50-year-old adults for colorectal, 50-year-old women for breast — and followed them across a simulated lifetime at 2016 baseline screening rates, then re-ran the model at higher screening levels. At the 2016 baselines of 79.9 percent for cervical and 67.7 percent for colorectal screening, raising participation to 90 percent would prevent 3,434 cervical cancer deaths and 24,530 colorectal cancer deaths over the lifetime of a single cohort. Raising it to 100 percent would prevent 6,834 cervical and 35,530 colorectal deaths. Those are not annual totals; they are the lifetime yield of closing the gap for one year's worth of Americans, and colorectal screening produces by far the largest return of the three cancers modeled.
CDC's chronic disease center puts the same finding in population terms: pushing colorectal screening prevalence to 80 percent would cut new colorectal cancer diagnoses by 22 percent and colorectal cancer deaths by 33 percent by 2030. A third of the deaths, removed by a participation rate — not a drug, not a surgical technique, not a new immunotherapy. The intervention already exists, is already recommended, and is already covered as preventive care under most insurance. What is missing is the visit.
Why the Visit Doesn't Happen
The barriers documented in the screening literature are boring, which is part of why they persist. Colonoscopy requires a bowel prep, a day off work, and a ride home from sedation — three separate logistical demands on people whose jobs do not accommodate any of them, though stool-based tests like FIT and multitarget stool DNA testing exist precisely to route around that and are recommended options under the same guideline. Cervical screening requires a pelvic exam, a category of care that a substantial share of women avoid, and it has historically been bundled into routine gynecologic visits that fewer young women now schedule — the JAMA Network Open authors note the never-screened increase accelerated after 2010, alongside changes in guideline intervals, contraceptive care patterns, and where young adults get primary care at all. Longer recommended screening intervals, which are clinically sound, also mean that a person who slips out of the schedule has fewer scheduled reminders pulling them back in. And for the uninsured, the arithmetic is simply that a preventive test without symptoms loses to every bill that has already arrived.
And Then You're Dead
A cervical or colorectal cancer death in America is rarely the story of a cancer that could not be beaten. It is the story of a cancer that got a head start of several years, in silence, while the precursor lesion that a routine test would have found sat there being findable. The treatment that would have worked was the one that was never needed. Ninety-one percent of people survive it when it is caught in place. Seventeen percent survive it once it has traveled. Between those two numbers there is no medical breakthrough — only an appointment.
That's it. That's the whole thing.
Sources
- Five-year relative survival by stage for colorectal cancer (localized 91.3%, regional 75.2%, distant 16.9%; 65.4% overall, cases 2016–2022), stage distribution at diagnosis (34% localized, 37% regional, 23% distant, 6% unknown), the 12.7 per 100,000 death rate for 2020–2024, and 2026 projections of 158,850 new cases and 55,230 deaths — National Cancer Institute, Surveillance, Epidemiology, and End Results Program, "Cancer Stat Facts: Colorectal Cancer"
- Five-year relative survival by stage for cervical cancer (localized 91.8%, regional 64.0%, distant 20.5%; 68.8% overall, cases 2016–2022), stage distribution at diagnosis (41% localized, 37% regional, 16% distant, 6% unknown), the 2.1 per 100,000 death rate for 2020–2024, and 2026 projections of 13,490 new cases and 4,200 deaths — National Cancer Institute, Surveillance, Epidemiology, and End Results Program, "Cancer Stat Facts: Cervical Cancer"
- Colorectal screening up-to-date prevalence by age in 2023 (45–49: 37.1%, 95% CI 34.5–39.7; 50–64: 67.8%; 65–75: 82.7%), cervical screening prevalence overall (75.4%) and by age (21–29: 63.7%; 30–39: 82.7%; 40–49: 76.5%), and colorectal screening by insurance status among adults under 65 (private insurance 64.7%, uninsured 23.8%) — "Use of Cancer Screening Tests, United States, 2023," Preventing Chronic Disease, Centers for Disease Control and Prevention, 2025, using National Health Interview Survey 2023 data
- Never-screened cervical cancer trends: women aged 21–29 rising from 12.5% (3.5 million) in 2005 to 31.9% (6.2 million) in 2023, average annual percentage change 5.2%; women aged 30–65 rising from 5.3% (4.3 million) to 14.8% (9.2 million), average annual percentage change 6.8%; and HPV vaccination among women 21–29 rising from 5.7% in 2008 to 54.0% in 2019 — Sonawane K, Damgacioglu H, Amboree TL, et al., "Rates of Never Receiving Cervical Cancer Screening Among US Women, 2005–2023," JAMA Network Open, August 27, 2026, using National Health Interview Survey cycles 2005–2023
- The 11.4% of women aged 21–65 not screened for cervical cancer in the past five years, 23.1% among uninsured women and 25.5% among women without a regular provider, the South's 2.7 per 100,000 death rate, and the finding that over half of new cervical cancer cases occur in women never or rarely screened — "Vital Signs: Cervical Cancer Incidence, Mortality, and Screening — United States, 2007–2012," CDC Morbidity and Mortality Weekly Report
- Modeled deaths prevented by increasing screening participation from 2016 baselines (cervical 79.9%, colorectal 67.7%): 3,434 cervical and 24,530 colorectal deaths prevented at 90% participation, 6,834 cervical and 35,530 colorectal at 100%, over the lifetime of a single-year cohort — Sharma KP, et al., "Preventing Breast, Cervical, and Colorectal Cancer Deaths: Assessing the Impact of Increased Screening," Preventing Chronic Disease, Centers for Disease Control and Prevention, 2020
- The 61% of adults aged 45–75 up to date with colorectal screening in 2022, and the projection that 80% screening prevalence would reduce colorectal cancer diagnoses by 22% and deaths by 33% by 2030 — CDC National Center for Chronic Disease Prevention and Health Promotion, "Health and Economic Benefits of Colorectal Cancer Interventions," using Behavioral Risk Factor Surveillance System 2022 data
- The 2021 lowering of the recommended colorectal cancer screening start age from 50 to 45 for average-risk adults, and the inclusion of stool-based tests among recommended screening options — U.S. Preventive Services Task Force, Colorectal Cancer: Screening, final recommendation statement, 2021
- Photo: "Hospitalman Urian D. Thompson, Lt. Cmdr. Eric A. Lavery and Registered Nurse Steven Cherry review the monitor while performing a colonoscopy," U.S. Navy, public domain, via Wikimedia Commons
Comments
Loading…